What's new

Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised

Jun 26, 2025 - 13:50
 0
Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Phesgo, pertuzumab,trastuzumab, Date of authorisation: 21/12/2020, Revision: 6, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Pavblu, aflibercept, R...

Next Article

Human medicines European public assessment report (EPAR): Januvia, sitagliptin, ...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Trimbow, beclometasone dipropionate,formoterol fumarate dihydrate,glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Respiratory, thoracic and mediastinal disorders, PIP number: P/0167/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 16, 2025  0

EMEA-003586-PIP01-24

EMEA-003586-PIP01-24

Jun 24, 2025  0

Orphan designation: single guide RNA targeting the human TTR gene, Ziclumeran Treatment of ATTR amyloidosis, 26/03/2021 Positive

Orphan designation: single guide RNA targeting the huma...

Jun 5, 2025  0